A prospective trial of the incidence of deep venous thrombosis as detected by the 125I-labelledfibrinogen technique was performed in patients with acute myocardial infarction. One hundred and sixteen patients completed the trial and were randomly allocated full therapeutic heparin dosage intravenously (63 patients), while control patients received I,OOO units of heparin daily. The incidence of venous thromboses in the control group was not significantly different from the therapeutic group (I2.7% and 9 4%, respectively). The previously documented low incidence of clinicalfeatures of calf vein thrombosis was confirmed.
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A high incidence of venous thromboses was shown in patients with cardiac failure (I7%), and in this subgroup full anticoagulant dosage was associated with a significant reduction. The trial was terminated as no overall difference was apparent, and the incidence of venous thromboses was lower than in other studies where anticoagulants had not been used. The latter suggests that very low doses of heparin reduce the incidence without the risk of haemorrhagic complications. A further prospective trial with addition of a group receiving no heparin is presently being undertaken.
Over the past 12 years the technique of using radioactively labelled fibrinogen, with external scintillation counting, has been developed to detect venous thrombosis in the legs (Hobbs and Davies, I960; Palko, Nanson, and Fedoruk, I964; Atkins and Hawkins, I965, I968; Nanson et al., I965) . Where an increased uptake of the isotope has occurred, phlebography has confirmed the presence of venous filling defects. The incidence of venous thromboses in patient groups studied has been shown to be higher than detected clinically, and the use of this method has become widely accepted because of its simplicity and diagnostic accuracy (Kakkar, Flanc, and Tsapogas, I968; Flanc, Kakkar, and Clarke, I968; Negus et al., I968; Kakkar et al., I97oa, b; Lambie et al., 1970) .
The management of myocardial infarction is usually characterized by a period of relative immobility, and may be complicated by the development of venous thromboses and pulmonary thromboembolic disease. One of the major indications for the use of anticoagulants in the management of acute myocardial infarction has been in the prevention of venous thrombosis (Ebert, I972 Recent reports using radioactively labelled fibrinogen have shown a much higher incidence than had previously been recognized (Murray et al., I970; Maurer, Wray, and Shillingford, I971; Maurer, I970; Nicolaides et al., I97I) .
We have studied the incidence of venous thromboses in the legs of patients with acute myocardial infarction, and an attempt has been made to determine whether anticoagulation affects this incidence.
Patients and methods
The patients studied in the trial were all admitted to the Coronary Care Unit of the Alfred Hospital where a diagnosis of acute myocardial infarction was confirmed by standard electrocardiographic criteria and serum enzyme changes (aspartate aminotransferase and lactate dehydrogenase). Fifty-five patients with an acute myocardial infarction were excluded as they either had contraindications to the use of anticoagulants or had received them before admission and so could not be randomized. Eighteen patients were excluded because of cardiogenic shock on admission, ii because of the insertion of a transvenous pacemaker, and 7 because the infarct had occurred more than 48 hours previously. Twenty-three patients were not included because of technical problems with the scintillation counter or supply of 125I, and one as the patient had only one leg.
A number of patients were initially randomized and later withdrawn from the study because the clinical On admission to the coronary care unit assessment was made as to whether or not the patient was in cardiac failure, based on the presence of a third heart sound, basal moist sounds not clearing on coughing, or the appearance of radiological evidence of pulmonary venous congestion. The patients who developed cardiac failure had greater peak serum enzyme levels with the mean serum aspartate aminotransferase level being 284 Reitman-Frankel units compared with I83 ReitmanFrankel units in patients with no cardiac failure. The same pattern was noted with serum LDH levels.
The incidence of venous thrombosis in patient groups and subgroups was compared using the x2 test corrected for continuity.
Results
Of the i i6 patients who completed the study period, I3 showed an increased uptake as evidence of deep venous thrombosis, an overall incidence of I I -2 per cent. The incidence in the 63 control patients was I2v7 per cent (8 patients), compared with 9.4 per cent (5 patients) of the 53 who were anticoagulated; this difference was not statistically significant (Table 2 ). There were no apparent differences as to age, sex, surface area, or time from infarction to admission between those developing thromboses and the overall group.
Cardiac failure was present in 22 patients in the control group, of whom 27 per cent developed venous thrombosis (6 patients), while in 20 patients who were anticoagulated none developed venous thromboses (Table 3) . When cardiac failure was not present the incidence was 5 and I5 per cent, respectively (Table 4 ). Only the difference in the incidence in patients with cardiac failure was statistically significant (P < o os).
The length of confinement to bed which ranged from 2 to I0 days after admission did not affect the incidence of thrombosis. Five thromboses were transient lasting less than 48 hours, with the remaining 8 persisting up to io days (Table 5 ). Seven Of the I3 patients with venous thrombosis, only 3 had clinical signs, one having an increased uptake of fibrinogen 24 hours before calf tenderness was elicited.
Three patients in the series died while still in the hospital, i from a further myocardial infarction on the I3th day, i from progressive cardiac failure associated with an acute ventricular septal defect, and the third from severe cardiac failure of long standing. The latter patient, who was in the control group, had a history of calf pain one week before admission, and died on the seventh day several hours after recurrence of chest pain. Necropsy confirmed recent myocardial infarction in all 3 patients, and pulmonary embolism and venous thrombosis of the deep veins in the right calf was present in the third patient. This was presumably not detected as the thrombus was probably present 7 days before labelled fibrinogen was given, and was thus not incorporated into the thrombus.
Discussion
The incidence of deep thrombosis and acute myocardial infarction as determined by the 125I-labelled fibrinogen technique in patients not receiving anticoagulants has been reported to be 34 per cent by Murray et al. (1970) , 37 per cent by Maurer et al. (I97i), and 38 per cent by Nicolaides et al. (I97I) .
Pooling the results of these groups gives an incidence of 5I thromboses in 138 patients, i.e. 37 per cent. Nicolaides et al. (I97I) , in a small series of 13 patients, showed a reduction in incidence with the use of full dose anticoagulants to 5-5 per cent. In the presently reported series, we found an incidence of 9.4 per cent in a group of 53 receiving full dosage anticoagulants. It appears that the incidence of venous thrombosis is significantly reduced by the use of standard therapeutic doses of anticoagulants.
In preparing a protocol for the current trial, it was decided to give control patients 500 units of heparin intravenously i2-hourly, as was the current practice at the Alfred Hospital in patients receiving dextrose infusion, because it was thought that it would reduce the incidence of infusion obstruction. At the onset of the trial, it was not felt that the small dosage of heparin used would influence the results. The incidence in the control group was not found to be significantly different from those fully anticoagulated, thus implying that small doses of heparin appear as effective as the full therapeutic regimen in the prevention of venous thrombosis.
Low dosage heparin has been shown in postoperative surgical patients to reduce the frequency of deep venous thrombosis (Sharnoff, Kass, and Mistica, I962; Sharnoff, I966; Sharnoff and DeBlasio, I970; Kakkar et al., I97I; Gordon-Smith et al., 1972) , though these series used at least io,ooo units of heparin daily without alteration of whole blood clotting time or thrombin clotting time.
The mechanism of action of low dosage heparin remains unknown at the present time, though several theories have been postulated. In ischaemic heart disease, McDonald and Edgill (I957) have shown increased platelet stickiness, and Slack et al. (I964) found that lipoprotein lipase activity was significantly lower in this group. Negus, Pinto, and Slack (I97i) and Ham and Slack (I968) demonstrated that intravenous heparin in small dosage (i-io units per kg) reduces the increased postoperative platelet adhesiveness, this being accompanied by a rise in lipoprotein lipase activity. Yin and Wessler (1970) have suggested that heparin enhances the activity of a potent naturally occurring inhibitor to activated factor X, without altering the whole blood clotting time. Nicolaides et al. (I97I) , in a small group of patients with acute myocardial infarction, suggest that there is an increased incidence of venous thromboses in those patients who are 'severely ill'. In the current series no significant difference in the incidence of venous thromboses was found when patients with and without failure were compared (P > 0-5). However, when the patients in cardiac failure are subdivided into those receiving full and low dose anticoagulation, a significant difference appears in favour of the full dosage group. Among the patients without cardiac failure, there was an increased incidence of venous thrombosis in those patients receiving anticoagulants (I5% compared with 5%): this figure was not significant. Of the 5 patients in this group receiving anticoagulants, 4 were the only patients to show an increased uptake on the first day of counting, and it could be postulated that these 4 patients were laying down thrombus at the time of admission, so that labelled fibrinogen was incorporated before the therapeutic effect of the anticoagulant regimen. Analysis of these 4 patients showed no apparent differences in age, surface area, or time from infarction to admission from the remainder of the groups; however, all were male patients. If these 4 patients are excluded from the overall series, then there is a reduction in incidence in the anticoagulated patients to 2 (197oa) showed a high incidence of venous thromboses in postoperative patients who had had a previous leg vein thrombosis, and a I00 per cent incidence in those with a previous history of pulmonary embolism. In our study only a single patient had a history of venous thrombosis and pulmonary embolism, and she did not show any increased uptake of isotope at this admission, even though she was randomized to the control group.
The results of the current study suggest that very low dose heparin provides the same benefit as full dose anticoagulation in the prophylaxis against venous thrombosis in patients with acute myocardial infarction who are not in cardiac failure. Confirmation of these data will allow the benefits of low dose heparin therapy to be extended to those in whom anticoagulants have previously been contraindicated. In the presence of cardiac failure it appears that some benefit is achieved, but in the current small series, full dosage heparin was more effective.
As fibrinogen is derived from pooled sera, there is a risk of transmission of the virus of serum hepatitis, and Laiwah et al. (1970) reported two cases of hepatitis with positive Australia antigen five months after the injection of 125I-labelled fibrinogen. We have used fibrinogen from a carefully screened group of donors in order to reduce this risk, and no case of hepatitis has occurred among the patients studied in the present series or among approximately 5oo other studies at the Alfred Hospital. We have detected no complications with the usage of the labelled fibrinogen technique. This trial was concluded after i i6 patients had been studied, as no statistical difference could be shown in the incidence of deep venous thrombosis in the group receiving full dosage compared with the group receiving low dosage heparin. A further prospective trial is being undertaken in acute myocardial infarction comparing the use of no anticoagulants, i,000 units of heparin intravenously daily, and full therapeutic dosage of heparin, on the incidence of venous thromboses. 
